Literature DB >> 10987309

Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts.

E K Rofstad1, E F Halsør.   

Abstract

Angiogenesis is a significant prognostic factor in melanoma, but the angiogenic factors controlling the neovascularization are not well defined. The purpose of this study was to investigate whether the angiogenesis and metastasis of melanoma are promoted by vascular endothelial growth factor (VEGF), interleukin 8 (IL-8), platelet-derived endothelial cell growth factor (PD-ECGF), and/or basic fibroblast growth factor (bFGF). Cells from human melanoma lines (A-07, D-12, R-18, and U-25) transplanted to BALB/c nu/nu mice were used as tumor models. Expression of angiogenic factors was studied by ELISA, Western blotting, and immunohistochemistry. Angiogenesis was assessed by using an intradermal angiogenesis assay. Lung colonization and spontaneous lung metastasis were determined after i.v. and intradermal inoculation of tumor cells, respectively. The specific roles of VEGF, IL-8, PD-ECGF, and bFGF in tumor angiogenesis, lung colonization, and spontaneous metastasis were assessed in mice treated with neutralizing antibody. The melanoma lines expressed multiple angiogenic factors, and each line showed a unique expression pattern. Multiple angiogenic factors promoted angiogenesis in the most angiogenic melanoma lines, whereas angiogenesis in the least angiogenic melanoma lines was possibly promoted solely by VEGF. Tumor growth, lung colonization, and spontaneous metastasis were controlled by the rate of angiogenesis and hence by the angiogenic factors promoting the angiogenesis. Lung colonization and spontaneous metastasis in A-07 were inhibited by treatment with neutralizing antibody against VEGF, IL-8, PD-ECGF, or bFGF. Each of these angiogenic factors may promote metastasis in melanoma, because inhibition of one of them could not be compensated for by the others. Our observations suggest that efficient antiangiogenic treatment of melanoma may require identification and blocking of common functional features of several angiogenic factors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10987309

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  55 in total

Review 1.  Angiogenesis and melanoma.

Authors:  J P Dutcher
Journal:  Curr Oncol Rep       Date:  2001-07       Impact factor: 5.075

Review 2.  From genes to drugs: targeted strategies for melanoma.

Authors:  Keith T Flaherty; F Stephen Hodi; David E Fisher
Journal:  Nat Rev Cancer       Date:  2012-04-05       Impact factor: 60.716

3.  Significance and relationship between infiltrating inflammatory cell and tumor angiogenesis in hepatocellular carcinoma tissues.

Authors:  Shao-Hua Peng; Hong Deng; Jian-Feng Yang; Ping-Ping Xie; Cheng Li; Hao Li; De-Yun Feng
Journal:  World J Gastroenterol       Date:  2005-11-07       Impact factor: 5.742

4.  Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas.

Authors:  O Straume; L A Akslen
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

5.  Novel biomarkers and therapeutic targets for optimizing the therapeutic management of melanomas.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  World J Clin Oncol       Date:  2012-03-10

Review 6.  From delocalized lipophilic cations to hypoxia: blocking tumor cell mitochondrial function leads to therapeutic gain with glycolytic inhibitors.

Authors:  Metin Kurtoglu; Theodore J Lampidis
Journal:  Mol Nutr Food Res       Date:  2009-01       Impact factor: 5.914

7.  Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment.

Authors:  Helena Harlin; Yuru Meng; Amy C Peterson; Yuanyuan Zha; Maria Tretiakova; Craig Slingluff; Mark McKee; Thomas F Gajewski
Journal:  Cancer Res       Date:  2009-03-17       Impact factor: 12.701

8.  A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma.

Authors:  Richard D Carvajal; Michael K Wong; John A Thompson; Michael S Gordon; Karl D Lewis; Anna C Pavlick; Jedd D Wolchok; Patrick B Rojas; Jonathan D Schwartz; Agop Y Bedikian
Journal:  Eur J Cancer       Date:  2014-06-12       Impact factor: 9.162

9.  Neurotensin/IL-8 pathway orchestrates local inflammatory response and tumor invasion by inducing M2 polarization of Tumor-Associated macrophages and epithelial-mesenchymal transition of hepatocellular carcinoma cells.

Authors:  Pei Xiao; Xinxin Long; Lijie Zhang; Yingnan Ye; Jincheng Guo; Pengpeng Liu; Rui Zhang; Junya Ning; Wenwen Yu; Feng Wei; Jinpu Yu
Journal:  Oncoimmunology       Date:  2018-03-13       Impact factor: 8.110

10.  F-Prostaglandin receptor regulates endothelial cell function via fibroblast growth factor-2.

Authors:  Margaret C Keightley; Pamela Brown; Henry N Jabbour; Kurt J Sales
Journal:  BMC Cell Biol       Date:  2010-01-21       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.